About Innocoll

Innocoll is a specialty pharmaceutical company committed to improving the status quo and finding answers to unmet needs

About Us

XARACOLL® (bupivacaine HCl) Implant

Our lead product, XARACOLL, was approved by the U.S. Food and Drug Administration in August 2020

XARACOLL

Latest News

Innocoll to Partner with Mallinckrodt Acute Care Sales Team to Support the Launch of XARACOLL® (bupivacaine HCl) implant

19 Oct
Mallinckrodt’s hospital sales force to begin promoting recently approved XARACOLL®, a first-of-its-kind, fully bioresorbable collagen implant that delivers bupivacaine HCI...
Read More

FDA Approves XARACOLL® (bupivacaine HCl) Implant, a Non-opioid, Drug-device Treatment Option for Acute Postsurgical Pain Relief for up to 24 Hours Following Open Inguinal Hernia Repair in Adults

31 Aug
XARACOLL is a first-of-its-kind, fully bioresorbable collagen implant that delivers bupivacaine HCl directly to the surgical site providing long-lasting pain...
Read More

Innocoll Holdings Limited Announces FDA Acceptance of New Drug Application for XARACOLL® for the Management of Postsurgical Pain

26 Mar
- FDA Sets Prescription Drug User Fee Act (PDUFA) Goal Date of August 26, 2020- ATHLONE, Ireland, March 26, 2020...
Read More

Business Development Group
Unit 9, Block D
Monksland Business Park
Monksland
Athlone
Co. Roscommon
Ireland

Phone: +353 (0)90 648 6834
Fax: +353 (0)90 648 6835
E-mail: inquiries@innocoll.com

Innocoll Holdings Limited, a private company limited by shares, incorporated in Ireland having company number 544604 and its registered office at 70 Sir John Rogerson’s Quay, Dublin 2, Ireland.

© 2020-2004 Innocoll. All rights reserved.
All Trademarks are owned by Innocoll Pharmaceuticals Limited